fda shortage list semaglutide Declares of Novo Nordisk's Wegovy, Ozempic Over Navigating changes in access to

The spots themselves may also appear darker and take longer to correct, which is why a protocol that is calibrated to phototype produces better results than a one-size-fits-all approach

Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality

Because breastfeeding places significant demands on the body and long-term infant safety data is limited, most clinicians recommend waiting until after weaning before considering GLP-1 medications

Abruptly stopping a GLP-1 can mean rebound appetite, weight regain, and worsening blood sugar control

The Wegovy pill (oral semaglutide 25 mg) produced an average weight loss of 13.6% in the OASIS 4 trial, broadly the same as the standard 2.4 mg injection and less than Mounjaro or the 7.2 mg injection

Trulicity (dulaglutide) This once-weekly injection is approved for treating type 2 diabetes and obesity